Bayer HealthCare Pharmacuticals

Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. It markets  products in more than 100 countries and in 2011 the company generated sales of almost € 10 billion. More than 37,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,500 in research and development alone.   Operations are concentrated on five big therapeutic groups: Cardiovascular and blood diseases Oncological diseases Ophthalmology Women's healthcare Imaging techniques   We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business.   Therapeutic Areas Age-related macular degeneration (AMD) Breast cancer Central retinal vein occlusion (CRVO) Colorectal Cancer (CRC) Contraception Diabetes Diabetic macular edema (DME) Endometriosis Erectile dysfunction Gastrointestinal stromal tumor (GIST) Gynecological therapy Heart attack Heart attack and stroke Hemophilia High blood pressure Infectious diseases Liver cancer Menopausal complaints Multiple sclerosis Peripheral arterial occlusive disease Premenstrual dysphoric disorder (PMDD) Prostate cancer Pulmonary arterial hypertension Renal cell carcinoma Stroke Testosterone deficiency Thrombosis Thyroid cancer   Research Areas In its internal research for active ingredients, Bayer HealthCare Pharmaceuticals concentrates on four core areas: Oncology, Cardiology, Women´s Healthcare, and Diagnostic Imaging. With new approaches in cancer therapy, cardiovascular diseases, gynecological therapies, and molecular imaging, we aim to become the innovation leader in these areas.